Balancing the Risk of Cardiotoxicity Outcomes in Treatment Selection for Multiple Myeloma: A Retrospective Multicenter Evaluation of Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (KRd)

EJHaem Pub Date : 2025-04-28 DOI:10.1002/jha2.70038

Benjamin J. Lee, Michael Sayer, Ali A. Naqvi, Karen T. Mai, Pranav M. Patel, Lisa X. Lee, Aya F. Ozaki

{"title":"Balancing the Risk of Cardiotoxicity Outcomes in Treatment Selection for Multiple Myeloma: A Retrospective Multicenter Evaluation of Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (KRd)","authors":"Benjamin J. Lee, Michael Sayer, Ali A. Naqvi, Karen T. Mai, Pranav M. Patel, Lisa X. Lee, Aya F. Ozaki","doi":"10.1002/jha2.70038","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Carfilzomib use has been extensively associated with cardiovascular toxicity; the risk with ixazomib, a novel oral proteasome inhibitor, is underreported and no large comparative analysis is available.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We conducted a retrospective cohort study utilizing the TriNetX platform to compare toxicity outcomes among multiple myeloma patients who received lenalidomide, dexamethasone, and ixazomib (IRd) or carfilzomib (KRd).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>After propensity-score-matching 478 patients from each cohort, the onset of new heart failure (HR 0.25; <i>p </i>< 0.001) and arrhythmias (HR 0.57; <i>p</i> = 0.014) at 6 months were significantly lower with IRd while overall survival at 3 years was similar (<i>p</i> = 0.50).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>IRd is associated with a significantly lower risk of cardiac toxicities compared to KRd.</p>\n </section>\n </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70038","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJHaem","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jha2.70038","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Carfilzomib use has been extensively associated with cardiovascular toxicity; the risk with ixazomib, a novel oral proteasome inhibitor, is underreported and no large comparative analysis is available.

Methods

We conducted a retrospective cohort study utilizing the TriNetX platform to compare toxicity outcomes among multiple myeloma patients who received lenalidomide, dexamethasone, and ixazomib (IRd) or carfilzomib (KRd).

Results

After propensity-score-matching 478 patients from each cohort, the onset of new heart failure (HR 0.25; p < 0.001) and arrhythmias (HR 0.57; p = 0.014) at 6 months were significantly lower with IRd while overall survival at 3 years was similar (p = 0.50).

Conclusion

IRd is associated with a significantly lower risk of cardiac toxicities compared to KRd.

Abstract Image

查看原文本刊更多论文

在多发性骨髓瘤治疗选择中平衡心脏毒性结局的风险：伊沙唑米、来那度胺和地塞米松（IRd）与卡非佐米、来那度胺和地塞米松（KRd）的回顾性多中心评价

卡非佐米的使用与心血管毒性广泛相关；ixazomib（一种新型口服蛋白酶体抑制剂）的风险被低估，也没有大型的比较分析。方法：我们利用TriNetX平台进行了一项回顾性队列研究，比较了来那度胺、地塞米松和伊沙唑米（IRd）或卡非佐米（KRd）治疗的多发性骨髓瘤患者的毒性结局。结果每组478例患者进行倾向评分匹配后，新发心力衰竭发生率(HR 0.25；p & lt;0.001)和心律失常(HR 0.57；p = 0.014) 6个月时的总生存率显著低于IRd，而3年的总生存率相似（p = 0.50）。结论与KRd相比，IRd与心脏毒性风险显著降低相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

EJHaem

自引率

0.00%

发文量